03.14.26 -- Outsourced Pharma Best Of February

Three reports, on oligonucleotide CDMOs, mRNA manufacturing, and bioconjugation, show where outsourcing is heading and highlight CDMOs growing role in industrializing advanced modalities.

At the JP Morgan Healthcare Conference, an intriguing anomaly occurred: out of eight biopharma roundtables, the session on U.S. Manufacturing drew no attendees. Here's a closer look.

A strong CDMO engages customers early to shape development and future manufacturing. An outsourcing expert shares his conversation approach.

Improve medication adherence and health outcomes by developing patient-friendly dosage forms that enhance swallowability and palatability for pediatric, geriatric, and dysphagic populations.

Sterile injectable manufacturing demands contamination control, rigorous monitoring, skilled personnel, and robust quality systems, far beyond sterility testing, to ensure safe, compliant CDMO performance.

Three factors often decide success or failure in FIH studies: integrating biomarkers and pharmacodynamic endpoints, and leveraging purpose-built manufacturing infrastructure.